FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156751520> ?p ?o ?g. }

• W3156751520 abstract "Background: Single-agent polatuzumab vedotin (pola) and obinutuzumab (G) demonstrated safety/clinical activity in separate B-cell non-Hodgkin lymphoma (B-NHL) trials.Methods: Open-label, non-randomised, phase 1b/2 study (ROMULUS) of patients with relapsed/refractory (R/R) B-NHL evaluating safety/efficacy of pola 1·8 mg/kg + G 1000 mg in 21-day cycles, up to eight cycles. Primary objectives were safety/tolerability and anti-tumour response.Findings: Eighty-eight patients were enrolled and received ≥1 dose of any study drug; 43 patients with R/R follicular lymphoma (FL) and 45 with R/R diffuse large B-cell lymphoma (DLBCL). Grade 3–4 AEs occurred in 48·5% (n=48/88) of patients, most commonly, neutropenia (18·6%; n=18). In R/R FL, the most frequent any-grade adverse event (AE) was fatigue (n=23/43; 53·5%) and in R/R DLBCL diarrhoea (n=16/45; 35·6%). In R/R FL, the complete response (CR) rate (by independent review committee) was 36·1% (n=13/36; 90% confidence interval [CI]: 22·9–51·2) with an objective response rate (ORR) of 66·7% (n=24/36; 90% CI: 51·7–79·5). The ORR in R/R DLBCL was 19·4% (n=6/31; 90% CI: 8·8–34·7; no CRs). In R/R FL, investigator-assessed median duration of response was 8·5 months (interquartile range [IQR]: 6×3–9×7) and in R/R DLBCL was 3·7 months (IQR: 3×3–not estimable [NE]); median progression-free survival was 11·5 months (IQR: 7×8-12×4) and 2·8 months (IQR: 1×5-6×3); and median overall survival was not reached and 10·7 months, respectively.Interpretation: While the anti-tumour activity of pola (1.8 mg/kg)-G in R/R DLBCL was modest, pola-G warrants further investigation as a treatment for R/R FL. Trial Registration: www.clinicaltrials.gov (NCT01691898).Funding Statement: F. Hoffmann-La Roche.Declaration of Interests: T.P. has received research support from AbbVie and Pharmacyclics, and reports advisory board participation for Genentech, Inc., Bayer, Gilead, Pharmacyclics, Incyte, and Seattle Genetics. M.B. has no disclosures; the clinical and intellectual work on this paper was performed prior to employment with the Cigna Corporation and does not reflect the opinions or support of the Cigna Corporation. A.I.C. has acted as a consultant and has received research funding from Genentech, Inc. J.E. has nothing to disclose. A.C. reports advisory board participation for Celgene, Janssen, and iQone, and has received lecture fees from Celgene, Janssen, F. Hoffman-La Roche Ltd, and Servier. C.D. has served as a consultant/advisory board participant for Bristol-Myers Squibb, Celgene, Merck, Genentech, Inc./F. Hoffman-La Roche Ltd, and Seattle Genetics, and has received research support from Seattle Genetics, Bristol-Myers Squibb, Merck, Genentech, Inc., Incyte, LAM Therapeutics, Millennium/Takeda, MEI Pharma, and Trillium. J.C. is an employee of F. Hoffmann-La Roche Ltd. D.R. was a consultant to Genentech, Inc. at the time the study was carried out. J.H. is an employee of Genentech, Inc. F.M. has participated in advisory boards for Celgene, F. Hoffman-La Roche Ltd, Gilead, Bristol-Myers Squibb, Epizyme, and Bayer, and reports receiving lecture fees from Celgene, Janssen, F. Hoffman-La Roche Ltd, and Novartis, and research support from AbbVie, Pharmacyclics, and advisory board fees from Genentech, Inc., Bayer, Gilead, Pharmacyclics, Incyte, and Seattle Genetics. I.W.F. has acted as a consultant for AbbVie, Seattle Genetics, TG Therapeutics, and Verastem Oncology, and has received research funding from Acerta Pharma, Agios, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Genentech, Inc., Gilead Sciences, Incyte, Infinity Pharmaceuticals, Janssen, Karo Pharma, Kite Pharma, Novartis, Pharmacyclics, Portola Pharmaceuticals, F. Hoffman-La Roche Ltd, TG Therapeutics, Trillium Therapeutics, AbbVie, ArQule, BeiGene, Curis Inc., FORMA Therapeutics, Forty Seven, Merck, Pfizer, Takeda, Teva, Verastem Oncology, Gilead Sciences, Astra Zeneca, Juno Therapeutics, Unum Therapeutics, and MorphoSys AG.Ethics Approval Statement: Institutional review boards/ethics committees approved the protocol. The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation guidelines for Good Clinical Practice, and country-specific laws and regulations. All patients provided written informed consent." @default.
• W3156751520 created "2021-04-26" @default.
• W3156751520 creator A5000959540 @default.
• W3156751520 creator A5014995908 @default.
• W3156751520 creator A5031968057 @default.
• W3156751520 creator A5042719564 @default.
• W3156751520 creator A5043356301 @default.
• W3156751520 creator A5044422916 @default.
• W3156751520 creator A5045191576 @default.
• W3156751520 creator A5046396205 @default.
• W3156751520 creator A5051605599 @default.
• W3156751520 creator A5061466414 @default.
• W3156751520 creator A5062534813 @default.
• W3156751520 date "2021-01-01" @default.
• W3156751520 modified "2023-09-27" @default.
• W3156751520 title "Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study" @default.
• W3156751520 cites W2029850226 @default.
• W3156751520 cites W2091057822 @default.
• W3156751520 cites W2121227413 @default.
• W3156751520 cites W2127018518 @default.
• W3156751520 cites W2134861285 @default.
• W3156751520 cites W2245171694 @default.
• W3156751520 cites W2310716991 @default.
• W3156751520 cites W2416458185 @default.
• W3156751520 cites W2622706981 @default.
• W3156751520 cites W2626812824 @default.
• W3156751520 cites W2744261860 @default.
• W3156751520 cites W2761878534 @default.
• W3156751520 cites W2762226752 @default.
• W3156751520 cites W2773804840 @default.
• W3156751520 cites W2781693040 @default.
• W3156751520 cites W2795058050 @default.
• W3156751520 cites W2803338071 @default.
• W3156751520 cites W2806889830 @default.
• W3156751520 cites W2886323375 @default.
• W3156751520 cites W2891571059 @default.
• W3156751520 cites W2903062212 @default.
• W3156751520 cites W2905757675 @default.
• W3156751520 cites W2925270992 @default.
• W3156751520 cites W2934686121 @default.
• W3156751520 cites W2984927918 @default.
• W3156751520 cites W2986196170 @default.
• W3156751520 cites W2989150180 @default.
• W3156751520 cites W4244510549 @default.
• W3156751520 cites W4250097730 @default.
• W3156751520 doi "https://doi.org/10.2139/ssrn.3800072" @default.
• W3156751520 hasPublicationYear "2021" @default.
• W3156751520 type Work @default.
• W3156751520 sameAs 3156751520 @default.
• W3156751520 citedByCount "0" @default.
• W3156751520 crossrefType "journal-article" @default.
• W3156751520 hasAuthorship W3156751520A5000959540 @default.
• W3156751520 hasAuthorship W3156751520A5014995908 @default.
• W3156751520 hasAuthorship W3156751520A5031968057 @default.
• W3156751520 hasAuthorship W3156751520A5042719564 @default.
• W3156751520 hasAuthorship W3156751520A5043356301 @default.
• W3156751520 hasAuthorship W3156751520A5044422916 @default.
• W3156751520 hasAuthorship W3156751520A5045191576 @default.
• W3156751520 hasAuthorship W3156751520A5046396205 @default.
• W3156751520 hasAuthorship W3156751520A5051605599 @default.
• W3156751520 hasAuthorship W3156751520A5061466414 @default.
• W3156751520 hasAuthorship W3156751520A5062534813 @default.
• W3156751520 hasConcept C126322002 @default.
• W3156751520 hasConcept C142424586 @default.
• W3156751520 hasConcept C143998085 @default.
• W3156751520 hasConcept C159985019 @default.
• W3156751520 hasConcept C192562407 @default.
• W3156751520 hasConcept C2777607594 @default.
• W3156751520 hasConcept C2778191690 @default.
• W3156751520 hasConcept C2779338263 @default.
• W3156751520 hasConcept C2780653079 @default.
• W3156751520 hasConcept C2992779791 @default.
• W3156751520 hasConcept C31760486 @default.
• W3156751520 hasConcept C535046627 @default.
• W3156751520 hasConcept C71924100 @default.
• W3156751520 hasConceptScore W3156751520C126322002 @default.
• W3156751520 hasConceptScore W3156751520C142424586 @default.
• W3156751520 hasConceptScore W3156751520C143998085 @default.
• W3156751520 hasConceptScore W3156751520C159985019 @default.
• W3156751520 hasConceptScore W3156751520C192562407 @default.
• W3156751520 hasConceptScore W3156751520C2777607594 @default.
• W3156751520 hasConceptScore W3156751520C2778191690 @default.
• W3156751520 hasConceptScore W3156751520C2779338263 @default.
• W3156751520 hasConceptScore W3156751520C2780653079 @default.
• W3156751520 hasConceptScore W3156751520C2992779791 @default.
• W3156751520 hasConceptScore W3156751520C31760486 @default.
• W3156751520 hasConceptScore W3156751520C535046627 @default.
• W3156751520 hasConceptScore W3156751520C71924100 @default.
• W3156751520 hasLocation W31567515201 @default.
• W3156751520 hasOpenAccess W3156751520 @default.
• W3156751520 hasPrimaryLocation W31567515201 @default.
• W3156751520 hasRelatedWork W2007965906 @default.
• W3156751520 hasRelatedWork W2021240435 @default.
• W3156751520 hasRelatedWork W2086296392 @default.
• W3156751520 hasRelatedWork W2593648047 @default.
• W3156751520 hasRelatedWork W2615545949 @default.
• W3156751520 hasRelatedWork W2946486395 @default.
• W3156751520 hasRelatedWork W3162448531 @default.
• W3156751520 hasRelatedWork W3210624555 @default.
• W3156751520 hasRelatedWork W4255392251 @default.

• next